Teligent is expanding its manufacturing and R&D complex in New Jersey.
Teligent, a New Jersey-based specialty generic-drug pharmaceutical company, held a formal groundbreaking ceremony for the ongoing expansion of its manufacturing and research and development complex in Buena, NJ, the company said in a July 6, 2016 press release. The $45â50 million project will increase the facility's footprint by more than 75,000 ft2, a 200% increase to current operations. Once completed, the expansion will include the installation of a new isolator-based sterile injectable manufacturing suite and will deliver a significant increase to the company's manufacturing capacity for topical pharmaceutical products.
''We are making very good progress on our expansion, and this ceremony was an opportunity to celebrate what we are building together,'' commented Teligent's president and CEO, Jason Grenfell-Gardner, in the press release. ''We continue to be on track for project completion by the end of 2017.''
Source: Teligent
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.